Osi Pharmaceuticals — Merger or Acquisition (April 2010)
13 slides from Osi Pharmaceuticals's merger presentation, Apr 1, 2010
Slide 1: Schedule 14A
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than
Slide 2: Astellas Offer to Acquire OSI
*************** *************** *************** *************** *************** Astellas Offer to Acquire OSI *************** *************** *************** *************** *************** Investor Presentation *************** *************** April 2010 *************** *************** *************
Slide 3: Executive Summary
Executive Summary • OSI’s share price has lagged that of its peers and its performance has fallen short of Wall Street expectations • Astellas’ $52 per share offer reflects the potential for both Tarceva and OSI’s pipeline products as well as the value of OSI's financial assets • This offer represen
Slide 4: OSI's Share Price Has Lagged Its Peers
OSI’s Share Price Has Lagged Its Peers • Prior to the announcement of Astellas’ tender offer on March 1, 2010, OSI’s share price had significantly underperformed its peers in the AMEX Biotechnology (BTK) index over the last several years Note: February 26, 2010 was the last trading day prior to publ
Slide 5: OSI's 2009 Financial Results Contribute to Underperformance of Its Stock
OSI’s 2009 Financial Results Contribute to Underperformance of Its Stock • OSI’s continued inability to exceed Wall Street estimates caused it to significantly underperform its peers in 2009 Wall Street EPS Consensus Estimates vs. Actual Results -10% -15% -6% 0% 0.50 $0.42 $0.42 0.40 $0.33 $0.31 $0.
Slide 6: Astellas' Current Offer Represents Full and Fair Value for OSI
Astellas’ Current Offer Represents Full and Fair Value for OSI • Based on information available to Astellas, $52 in cash per share represents a full and fair value for OSI • This represents both the value created by OSI to date as well as its future prospects • The offer stands in comparison to Wall
Slide 7: Wall Street Commentary on Tarceva Maintenance
Wall Street Commentary on Tarceva Maintenance • Astellas' offer attributes value to all of the potential label expansions for Tarceva, including maintenance approval. Wall Street research analysts generally do not see significant value associated with maintenance approval "The EU approval of Tarceva
Slide 8: Comparable P/E and PEG multiples
Comparable P/E and PEG multiples • On a growth-adjusted basis, Astellas’ $52.00 per share offer is a significant premium to other established pharmaceutical firms and firms with higher growth expectations 3.0x 2.5x 2.5 2.0 1.8x 1.7x 1.5x 1.5x 1.4x 1.5 1.1x 1.0x 1.0x 1.0x 1.0 0.9x 0.8x 0.8x 0.5 0.0 O
Slide 9: In Today's Dollars, OSI Won't Reach $52 Until After 2013
In Today’s Dollars, OSI Won’t Reach $52 Until After 2013 • Even if OSI’s shareholders believe the Company will successfully execute on its strategy for the next three and a half years, and achieve Wall Street’s earnings estimates, on a present value basis they still will not achieve the same value t
Slide 10: Biogen Idec's Share Price History During Icahn's Offer
Biogen Idec’s Share Price History During Icahn’s Offer • Biogen’s failed efforts to find a potential buyer resulted in share prices lower than pre-announcement levels October 1, 2007 – March 1, 2008 10/13/07: Biogen 12/12/07: Biogen ends 1/28/08: Icahn sends 90 announces it has its strategic review
Slide 11: Outcome of Buyer Discussions Can Be Completed Quickly
Outcome of Buyer Discussions Can Be Completed Quickly • OSI’s Board of Directors instructed OSI’s management and financial advisors to contact other parties to explore a transaction • The sales process should not be used as a delay tactic OSI has ample time to locate a bid greater than $52 that has
Slide 12: Conclusion
Conclusion • If OSI does not announce a deal soon, shareholders will have to choose: Stay the course with OSI Realize immediate value from Astellas’ offer • If they elect to stay the course with OSI, shareholders may face a rapid decline in OSI’s share price to pre-offer levels and Tarceva’s useful
Slide 13: Additional Information
***** ***** Additional Information Further details related to this announcement can be found on www.oncologyleader.com Media Contacts Brunswick New York +1 212 333 3810 Stan Neve Sarah Lubman Brunswick Hong Kong +852 9850 5033 Joseph Lo Information Agent Georgeson + 1 212 440 9872 Thomas Gardiner Ab
OSI Pharmaceuticals — Merger or Acquisition (April 2010) on 6ix